Sajjad Akbar Bhatti

Medical Director of Thoracic Cancers

University of Arkansas for Medical Sciences

faculty

6 h-index 22 pubs 152 cited

Research Areas

Cancer Treatment and Pharmacology Lung Cancer Diagnosis and Treatment Immunotherapy and Immune Responses Cardiovascular Function and Risk Factors Meta-analysis and systematic reviews Health disparities and outcomes Mesenchymal stem cell research Cancer-related molecular mechanisms research

Links

ORCID Lab Website Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Sajjad Akbar Bhatti's research focuses on the treatment and outcomes of non-small cell lung cancer, particularly in older adults with brain metastases. His work investigates the efficacy and safety of immune checkpoint inhibitors (ICIs) as a first-line treatment compared to chemotherapy, and their use as subsequent therapy. Bhatti has also examined the impact of combining ICIs with cranial radiation for this patient population. His publications explore various aspects of ICI therapy, including fixed versus continuous treatment durations and associated cardiotoxicity. Additionally, Bhatti has contributed to theoretical discussions on cancer, exploring the stem cell theory and its implications for translational research and drug development. His scholarship metrics include an h-index of 6, with 22 total publications and 152 citations.

Metrics

h-index: 6
Publications: 22
Citations: 152

Selected Publications

Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis (2025) DOI
An example of long-term remission in oligorecurrent relapsed small-cell lung cancer, following single modality radiation therapy (2025) DOI
Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation. (2025) DOI
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide. (2025) DOI
Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review. (2025) DOI
Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases (2024) DOI
Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care (2024) DOI
Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases (2023) DOI
Participation in a multidisciplinary institutional committee, “RQUEST,” to enhance quality improvement education, project design, and implementation for hematology/oncology fellows. (2023) DOI
Exploring the association between medical marijuana cardholder status and antiemetic overuse. (2023) DOI
Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench (2022) DOI
A RARE CASE OF DESMOPLASTIC SMALL ROUND CELL TUMOR WITH LEPTOMENINGEAL CARCINOMATOSIS (2022) DOI
Immune Checkpoint Inhibitors—Associated Cardiotoxicity (2022) DOI